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Abstract
Background: Anaemia is the most common haematological complication of HIV and associated with a high morbidity
and a poor prognosis. The pathogenesis of HIV-associated anaemia is poorly understood and may include a direct effect
of HIV on erythropoiesis. In vitro studies have suggested that specific HIV strains, like X4 that uses the CXCR4 co-
receptor present on erythroid precursors, are associated with diminished erythropoiesis. This co-receptor affinity is
determined by changes in the hypervariable loop of the HIV-1 envelope genome. In a previous case-control study we
observed an association between HIV and severe anaemia in Malawian children that could not be fully explained by
secondary infections and micronutrient deficiencies alone. We therefore explored the possibility that alterations in the
V1-V2-V3 fragment of HIV-1 were associated with severe anaemia.
Methods: Using peripheral blood nucleic acid isolates of HIV-infected children identified in the previous studied we
assessed if variability of the V1-V2-V3 region of HIV and the occurrence of X4 strains were more common in HIV-
infected children with (cases, n = 29) and without severe anaemia (controls, n = 30). For 15 cases bone marrow isolates
were available to compare against peripheral blood. All children were followed for 18 months after recruitment.
Results: Phylogenetic analysis showed that HIV-1 subtype C was present in all but one child. All V1-V2-V3 characteristics
tested: V3 charge, V1-V2 length and potential glycosylation sites, were not found to be different between cases and
controls. Using a computer model (C-PSSM) four children (7.8%) were identified to have an X4 strain. This prevalence
was not different between study groups (p = 1.00). The V3 loop characteristics for bone marrow and peripheral blood
isolates in the case group were identical. None of the children identified as having an X4 strain developed a (new) episode
of severe anaemia during follow up.
Conclusion: The prevalence of X4 strains in these young HIV-1-subtype-C-infected children that were most likely
vertically infected and naïve to anti-retroviral therapy can be considered high compared to previous results from Malawi.
It is unlikely that V1-V2-V3 fragment characteristics and HIV co-receptor affinity is an important feature in the
development of severe anaemia in Malawian children.
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Background
Anaemia is the most common haematological complica-
tion of HIV in adults and children worldwide [1-3] and is
associated with a reduced quality of life and a high mor-
bidity [4]. Inadequate erythropoiesis is generally consid-
ered to be the main pathophysiological mechanism of
HIV-associated anaemia [1,5,6]. Despite the obvious
medical importance of anaemia the aetiology of this
erythropoietic failure is still not well understood. Several
possible pathways have been investigated including
opportunistic infections, micronutrient deficiencies and
the more recently identified direct effect of HIV on eryth-
ropoiesis [3,7]. The induction of anaemia by specific
strains of HIV is an example of this direct of effect of HIV
[8].
Early in infection the HIV-1 population usually consist of
a strain that has the capacity to bind to both CD4 and the
co-receptor CCR5 (R5 strain)[9,10]. Later in infection a
broadening or switch occurs and HIV evolves to infect
cells expressing CD4 and the co-receptor CXCR4 (R4
strains) [10,11]. This switch is thought to occur in 50% of
infections and is associated with an accelerated loss of
CD4+ T-cells and progression to AIDS [12].
Like the T-helper cells, erythropoietic stem cells express
both CD4 and CXCR4 on their membrane[13,14].
Although productive infection is uncommon in erythroid
precursor cells [3], several in vitro studies have associated
X4 strains with cell death in erythroid and other cell lines
[7,15-17]. Another similarity between T-helper cells and
erythroid cells is the decline in both cell types during dis-
ease progression [3,7]. Large studies have suggested that
anaemia might even be a better predictor of mortality
than loss of CD4 cells or HIV load increase [5,18,19]. A
decline of 1 g/dL in the haemoglobin concentration was
associated with a greater increased hazard of death than a
halving of the absolute CD4 count or a log increase in
viral load [18]. The reversal of anaemia, again similar to
an increase in T-helper cells, was associated with a better
life expectancy [18,19]. Despite these similarities to T
cells, no study has evaluated if the decrease in erythrocytes
might be a direct or indirect consequence of an alternated
co-receptor affinity [16].
Co-receptor affinity is a consequence of changes in the
variable loops (V1-V2-V3) of the envelope protein (env) of
HIV-1. Especially a high V3 amino acid charge was found
to be associated to X4 co-receptor affinity [20-24] and sev-
eral models have been published to predict co-receptor
affinity using V3 data [25-28]. Changes to the V1-V2 frag-
ment appear to be more indirectly linked to X4 affinity
and are increasingly associated with a neutralizing anti-
body escape [29-37]. These changes include an increased
number of potential N-linked glycosylation sites in V1-V3
[30-35] and possibly an extended length of the (V1-)V2
fragment [29,36,37].
In a recent case-control study we found a strong associa-
tion between HIV and severe anaemia in African children
[38]. This association could partly be explained by oppor-
tunistic infections with micronutrient deficiencies playing
only a modest role. After correction for this an independ-
ent association remained which can be explained by a
direct effect of HIV on erythropoiesis. We hypothesized
that the occurrence of X4 strains and other alterations of
the hypervariable loops V1-V2-V3 of the HIV-1 env
genome would be associated with severe anaemia. Using
nucleic acid isolates of HIV-infected children with (cases)
and without (controls) severe anaemia we assessed the
prevalence of: (1) high V3 and total V1-V2-V3 amino acid
charge; (2) an extended V1-V2 length; (3) an increase of
potential N-linked glycosylation sites of the V1-V3 and V3
fragments; (4) a HIV-1 subtype C position specific scoring
matrix (C-PSSM) that predicts co-receptor usage[25].
Methods
In two hospitals in southern Malawi we recruited two
groups of children aged 6–60 months into a case-control
study on severe anaemia (Haemoglobin concentration < 5
g/dL) as previously described [38]. In short, a severely
anaemic child requiring a blood transfusion (Case, Hae-
moglobin concentration < 5 g/dL) was recruited at presen-
tation to hospital alongside two controls (Haemoglobin
concentration ≥ 5 g/dL). One control was recruited from
apparently healthy residents living within proximity of
the case-patient (Community Control, CC) the other ran-
domly selected at the outpatient department (Hospital
Control, HC). On enrolment, a standardized study ques-
tionnaire and physical examination were completed, and
blood samples were collected. In cases only, a bone mar-
row aspiration was performed under anaesthesia if the
clinical condition permitted. Nutritional Z-scores were
calculated in EPI info 2000 [39]. 'Wasting' (weight-for-
height), applied to children with Z-scores <-2. Children
requiring admission were treated in a study ward. All con-
ditions were managed according to standard protocols.
All three study groups (cases, HC and CC) were actively
followed at 1, 3, 6, 12 and 18 months. In addition, chil-
dren were passively followed by asking guardians to
return to study clinics whenever the child was sick. During
follow-up visits clinical data was collected and a periph-
eral blood haemoglobin concentration was determined.
Fully informed consent was obtained from a parent or
guardian in all three study groups. HIV testing was dis-
cussed after transfusion for the cases and on a follow-up
visit for controls. The study was approved by the ethics
committees of the College of Medicine, Malawi, and the
Liverpool School of Tropical Medicine, UK.BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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Laboratory tests on site
Haemoglobin was measured on site using a Hemocue sys-
tem (Angelholm, Sweden). A full blood and reticulocyte
count was performed by Coulter counter (Coulter,
Hialeah, Fla).
C-reactive protein (CRP) was analyzed in heparin plasma
on a Roche p800/p170 system (Roche, Switzerland). HIV
testing was performed using two rapid tests (Determine,
Abbott-Laboratories, Japan; Unigold, Trinity-Biotech, Ire-
land). Reactive results in children less than 18 months
and discordant outcomes were resolved by PCR. Lym-
phocyte subsets including CD4 cell counts were meas-
ured, during the second year of recruitment, by adding 50
μl of whole blood to TRUECOUNT absolute count tubes
(Becton Dickinson, USA) and incubated with 20 μl Mul-
tiTest reagent. After incubation and red cell lysis, the cells
were analysed on a Becton Dickinson FACSCalibur flow
cytometer and analysed using MultiSet software (Becton
Dickinson, USA). CD4 expressing T-cells were expressed
as percentage of the total lymphocyte population and age
adjusted cut-offs were used to define immunodefi-
ciency[40]. Peripheral blood samples were separated and
aliquots of serum and plasma were stored at -80C for later
testing.
DNA extraction and polymerase chain reaction (PCR)
DNA was isolated from the blood and bone marrow sam-
ples with a silica-guanidiniumthiocyanate based
method[41]. The target DNA (env gene) was amplified
using polymerase chain reaction (PCR) with a pair of tar-
get-specific sense and antisense primers (Figure 1) in a 96-
well 9700 thermocycler (Applied Biosystems, USA). First
a reverse transcriptase (RT)-PCR was performed using 10
μl of the eluated nucleic acid solution and Avian Myelob-
lastosis Virus reverse transcriptase (AMV-RT, Boehringer
Mannheim) to generate cDNA. Five microliter of the PCR
product was used with Amplitaq (Applied Biosystems,
USA) to amplify the V1-V2-V3 env (810 bp) gene frag-
ment, or in case this failed a combination of nested PCRs
was performed to amplify this region as fragments (prim-
ers Figure 1).
Sequencing and cloning
PCR products were directly sequenced with the ABI Prism
Big-dye Terminator v 1.1 Cycle Sequencing Kit in an ABI
Prism 377 DNA sequencer using multiple fluorescent dyes
(Applied Biosystems, USA). PCR fragments showing evi-
dence of recombinants or a dual infection were cloned
with TA TOPO cloning kit (Invitrogen, USA). For each
sample at least eight clones were sequenced and from
these a consensus sequence was made. All sequences were
manually analysed and assembled with CodonCode
Aligner (version 1.5.2.). Multiple sequences were aligned
with CLUSTAL W [42] and optimised manually with
BioEdit Sequence Alignment Editor (version 7.0.1).
Viral Load determination
The HIV-1 viral load in plasma was determined with an
in-house real-time PCR assay, with primers located in the
HIV-1 pol gene. Primer/probe sequences were: upstream
primer 5'TGC ATT YAC CATACC TAG T 3', downstream
primer 5'ATT GCT GGT GAT CCT TTC CA 3', and probe
5'AAA CAA TGA GAC ACC AGG GAT TAG ATA 3'. The
probe was 6-FAM labelled. The detection limit of this
assay was 5 HIV-1 RNA copies per reaction.
Phylogenetic analysis
Genetic subtypes were determined by phylogenetic analy-
sis. The env gene sequence fragments were aligned with
the corresponding reference sequences obtained from the
Los Alamos HIV sequence database [43]. Phylogenetic
reconstruction was carried out with Molecular Evolution-
ary Genetics Analysis (MEGA) software version 3.0. A
model based upon the Kimura two-parameter model with
pair wise deletion was used. Bootstrap values were based
on a generation of 1000 replicate trees. Newly found
recombinant forms were analysed using Simplot (version
3.5.1.0.) comparing recombinant sequences against a
background of reference sequences.
Potential N-linked glycosylation sites and Amino acid 
charges
All protein fragments containing Asparagine (N) and Ser-
ine (S) or Threonine (T) that were separated by any third
amino acid (X) other than Proline (P) were counted as a
glycosylation site (N-X-S/T) [44]. All possible glycosyla-
tion sites and the amino acid charges were counted for the
V3 and V1-V2-V3 fragment separately.
Subtype C-specific phenotype predictor (C-PSSM)
A C-PSSM predictor is available online [45]. This predictor
is based on the computational techniques presented in
the paper from Jensen and colleagues [25].
Statistics
We compared characteristics of HIV-infected cases to HIV-
infected controls using the Fisher exact and Chi-square
test (categorical data) and the t-test or Wilcoxon rank sum
test (continuous data). For 2 × N contingency tables the
Fisher-Freeman-Halton exact test was used. For all tests a
two-sided alpha of <0.05 was used to assess significance.
The tested sample size would be able to detect an odds
ratio of 8 or more assuming an X4 strain prevalence of 8%
in the control population, a power of 80% and an alpha
of 0.05. Analyses were performed using SPSS 12.0 (SPSS
inc, USA) and StatsDirect 2.6 (StatsDirect ltd, UK).BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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Results
Patient Characteristics
The current study was embedded into a larger case-control
study that followed children for an additional 18 months.
That study recruited 381 children with severe and 757
children without severe anaemia over a two year period.
Overall 1039 (91%) parents consented to HIV testing, 57
(5.0%) refused and 42 (3.7%) were lost to follow up
before counselling. Of all children tested 45 (13%) of
severely anaemic cases and 41 (6%) non-severely anaemic
controls were HIV-infected (p < 0.001). These 86 children
formed the current study population and their baseline
characteristics are described in Tables 1 and 2. Haemo-
globin levels were lower in cases than controls but reticu-
locyte counts were not different between the study groups
(p = 0.72). Of all HIV-infected children, cases were more
Table 1: Characteristics of the HIV-infected children per study group.
Cases Controls p
HIV-infected 45 41 n/a
Age (mean in months ± SD) 25.5 ± 14.1 28.8 ± 12.4 0.25
Sex (M:F) 18:27 23:18 0.14
Haemoglobin (mean in g/dL ± SD) 3.6 ± 0.7 9.3 ± 2.0 n/a
Reticulocytes (Median and IQR *10e9/L) 58.6 (30.3–93.1) n = 35 55.7 (34.7–86.0) n = 31 0.72
CRP>10 mg/L 38/42 (90%) 25/36 (69%) 0.02
Baseline characteristics of children with severe anaemia (cases, Hb<5.0 g/dL) as compared to those without severe anaemia (controls). SD: Standard 
deviation; IQR Inter Quartile Range; The number of children is only displayed if data was not available for all children.
PCR Primers used to amplify V1-V2-V3 fragment Figure 1
PCR Primers used to amplify V1-V2-V3 fragment. A display of the primer sequences used to amplify the V1-V3 frag-
ment located on the viral genome of the HIV-1 env protein. External PCR: primers indicated with a blue *. Internal PCR prim-
ers are indicated with a red * for the V regions and with a green * for the C regions.
C1 V1 V2 C2 V3 C3
 
Primers used to amplify V1-V2-V3 
 
 
 
Primer ID  Primer name  Sequence 5’-3’ 
V1V2 primers   
*5’V1V2-1  A0383  TGT GTA CCC ACA GAC CCC AAC CC 
*5’V1V2-2-SP6  A0384  ATT TAG GTG ACA CTA TAG 
*3’V1V2-3-T7  A0387  TAA TAC GAC TCA TAG GG 
*3’V1V2-4  A0389  ATT CCA TGT GTA CAT TGT ACT G 
V3 primers   
*5’non BV3 in  A2603  AAT GTC AGC ACA GTA CAA TG 
*5’non BV3 out  A2602  CCA GTG GTA TCA ACT CAA 
*3’ non BV3 in  A2604  AT TTC TAA GTC CCC TCC TGA 
*3’ non BV3 out  A2605  TCT CCT CCT CCA GGY CTG AA 
V1V2V3 primers   
*5’V1V2-1  A0383  TGT GTA CCC ACA GAC CCC AAC CC 
*5’V1V2-2  A0385  GAG GAT ATA ATC AGT TTA TGG GA 
*3’V3  A2604  AT TTC TAA GTC CCC TCC TGA 
*3’V3  A2605  TCT CCT CCT CCA GGY CTG AA 
Overlap V1V2V3   
*5'V1V2-12  A3047  AAT TGC TCT TTC AAT GCA ACC ACA GA 
*3'V3-13  A3048  AGA ATG YTT GTC CTG GTC CTA T BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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likely to have been admitted to hospital in the past, were
more wasted, immunodeficient for age and had higher
plasma viral loads. Though the latter two results were only
tested in a subset of children, none of these differences
reached significance (Table 2). During follow-up, HIV-
infected children with severe anaemia had a significant
increased mortality (53%) compared to those without
severe anaemia (15%).
Sample Processing
Overall 29 (64%) of HIV-infected cases and 30 (73%) of
HIV-infected controls had samples available for further
analysis of the env fragment (Table 3). For one patient the
PCR failed, resulting in a recovery rate of 98%. For seven
other samples the env fragment could only be partially
amplified (V3 failed: n = 5 and C2 failed: n = 2). Cloning
was needed to determine consensus sequences for 14 sam-
ples. In one sample V1-V2 fragment the nucleotide differ-
ences were too large between clones, two consensus
sequences were made and separately analysed. However
V3 loops of these clones were found to be identical.
Degenerate base counts were taken into account and were
not different between cases and controls (p = 0.33, Table
3).
Phylogenetic analysis
Phylogenetic analysis of V1-V2 nucleotide sequences
showed that 57 of 58 isolates clustered with subtype C ref-
erence sequences (bootstrap value: 99%, Figure 2). Only
one child, a child recruited as control, had a new circulat-
ing recombinant form that showed similarity with CRF13-
cpx, which has genomic regions identified as subtypes A,
G, and J [46].
Amino acid charges V fragments
Amino-acid charges of the V3 loop and the total V1-V3
fragment are displayed in Figure 3 and 4 respectively. The
charges of the subtype C isolates ranged from +2 to +5
(V3) and from 1 to +7 (V1-V3) and were not significantly
different between the study groups (p = 0.19 and 0.36
respectively). Higher V3 charges (+5 or more) were found
in four isolates tested (7.7%), all in controls (Table 3).
Additional file 1 shows the amino acid logos for the V3
loop per study group. Alterations of the amino acid in
positions, 5–9, 11 and 25 of the V3 loop were not differ-
ent (p > 0.2 for all).
Potential N-linked glycosylation sites
All isolates contained one potential N-linked glycosyla-
tion site in the V3 loop. The number of potential glyco-
sylation sites on the V1-V3 fragment ranged between 10
and 17 (Figure 5) and was not different amongst cases and
controls (p = 0.75).
Table 3: Variability and predictors of co-receptor affinity per study group.
Cases Controls p
Available for testing 29/45 (64%) 30/41(73%) 0.38
PCR failed 0/29 1/30 1.00
Complete env product 25/29 26/29 1.00
Degenerate base counts (median, range) 2 (0–21) 4 (0–36) 0.33
Viral type C 29/29 28/29 1.00
V3 amino acid charge ≥ +5* 0/25 4/27 0.11
X4 strains (C-PSSM)* 2/25 2/27 1.00
Presence of several indicators of co-receptor affinity in children with severe anaemia (cases, Hb<5.0 g/dL) as compared to those without severe 
anaemia (controls). * according to C-PSSM score by Jensen [25], available at [45].
Table 2: Markers of disease progression and outcome study group.
Cases Controls p
Wasting (Z-score weight for height <-2) 7/36 (19%) 5/38 (13%) 0.46
Previous hospital admission 25/44 (57%) 16/41 (39%) 0.10
Mortality (18 months) 27/45 (60%) 6/41 (15%) <0.001
During admission 7/45 (16%) 0/41 (0%) 0.01
After discharge 20/38 (53%) 6/41 (15%) <0.001
Plasma viral load (mean ± SD in Log10/mL) 6.02 ± 1.08 n = 13 5.43 ± 0.85 n = 12 0.15
Severe immunodeficient (based on CD4%*) 9/16 (56%) 5/12 (42%) 0.45
Markers of disease progression in children with severe anaemia (cases Hb<5.0 g/dL) as compared to those without severe anaemia (controls). SD: 
Standard deviation; Viral loads were performed using a in-house methods as described in the method section. *According to the revised WHO 
guidelines CD4 <25% (6–12. months); <20% (12–35 months); <25% (36–59 months) [40].BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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Phylogenetic tree based on the V1-V2 fragment of the HIV-1 env gene nucleotide sequences Figure 2
Phylogenetic tree based on the V1-V2 fragment of the HIV-1 env gene nucleotide sequences. Phylogenetic tree to 
assess if the HIV-1 genome of children with severe anaemia (cases, Hb<5.0 g/dL) is different from those without severe anae-
mia (controls). Subtype A and CRF-13 reference sequences are used as outgroup sequence.BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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Length of the V1-V2 fragment
The distribution of the length of the V1-V2 fragment
ranged from 177 to 255 base pairs and is displayed in Fig-
ure 6. Mean length for cases was not significantly different
from controls (214 vs. 211 base pairs respectively, p =
0.55).
C-Position Specific Scoring Matrix
C-PSSM scores were used to predict co-receptor affinity for
HIV-1 subtype C strains using V3 loop data. Within our
study X4 tropism was found in 2 of 25 (8.0%) cases and 2
of 27 controls tested (7.4%, p = 1.0, Table 3). Both C-
PSSM results for the child with two different clones sug-
gested identical co-receptor affinity (CCR5). One of four
children identified with an X4 strain according to this
method had previously received a blood transfusion.
Bone Marrow isolates
Some studies have suggested different compartments of
the body may contain different viral strains. For 15 cases
bone marrow samples were available. Synonymous
changes in the amino acid sequences of the V3 fragments
between bone marrow and peripheral blood isolates were
observed in three children (20%). These patients showed
alterations of amino acid structure at position 25 (n = 2,
both e->d), and 29 (n = 1, n->d), changes that did not
effect the C-PSSM prediction.
Follow-up
After recruitment all children were followed during an 18
month follow-up period as part of this study. During this
follow-up period none of the four children (two cases and
two controls) that were infected with an R4 virus were
diagnosed with a (new) episode of severe anaemia. The
two cases died during follow up at 65 and 182 days from
recruitment from other causes than severe anaemia.
Distribution of V3 amino acid charges per study group Figure 3
Distribution of V3 amino acid charges per study group. Distribution of the nett charges of the V3 fragment in children 
with severe anaemia (cases, Hb<5.0 g/dL) as compared to those without severe anaemia (controls). The distribution is 
expressed as a percentage of the total number of codons analysed per study group (Controls: n = 28, Cases n = 26). Error bars 
express 95% Confidence intervals. p = 0.19.BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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Discussion
Severe anaemia is major cause of morbidity and mortality
in African children [47]. We previously reported that in an
urban environment as many as 21% of children admitted
with severe anaemia were HIV-infected which was more
than twice as prevalent as for the control population. This
association could only partly be explained by more prev-
alent secondary infections and an additional modest con-
tribution of nutrient deficiencies. A direct effect of HIV on
erythropoiesis was suspected and we assessed if HIV-1
envelope characteristics and co-receptor affinity were
associated with the occurrence of severe anaemia in these
children. In this first study to assess this association using
a case-control design, we found no variations in the
genetic domain of HIV env or the predicted prevalence of
X4 strains between children with and without severe anae-
mia.
HIV-1 subtype C appeared to be the most prevalent sub-
type in our sample. Previous reports on adults and chil-
dren in the region have confirmed that in Malawi HIV-1
subtype C is the most prevalent variant [48,49]. A new
recombinant form was identified in one of the control
children and showed similarities to CRF13-cpx, recently
found in Cameroon [50]. Since this strain is very different
from all other isolates found in Malawi, it might have
spread from Central Africa by the major transports route
running through the rural area in which this was found.
The phylogenetic tree based on the data from the env pro-
tein did not show clustering of cases as compared to con-
trols and argues against our hypothesis that specific
strains of HIV would predispose to the development of
severe anaemia. More specifically we assessed V3 amino
acid charge, overall V1-V2-V3 fragment charge, potential
N-linked glycosylation sites on the V1-V2-V3 and the V3
fragments, and V1-V2 length and did not identify any sig-
nificant difference between HIV-infected children with
and without severe anaemia.
Although much has been published on co-receptor affin-
ity for HIV-1 subtype B, the strain commonly found in
Distribution of total amino acid charge of the V1-V2-V3 fragment per study group Figure 4
Distribution of total amino acid charge of the V1-V2-V3 fragment per study group. Distribution of the nett charges 
of the V1-V2-V3 fragment in children with severe anaemia (cases, Hb<5.0 g/dL) as compared to those without severe anaemia 
(controls). The distribution is expressed as a percentage of the total number of fragments analysed per study group (Controls: 
n = 26, Cases n = 25). Error bars express 95% Confidence intervals. p = 0.36.BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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western settings, relatively little is known on HIV-1 sub-
type C and co-receptor affiliation. Recently Jensen et al.
published a validated algorithm to predict co-receptor
usage in subtype C [25]. This C-PSSM score predicted X4
affinity in four strains, two in each study group.
The X4-strain prevalence of 7.7% in the case and control
groups combined was higher than expected in this pre-
dominantly HIV-1 subtype C infected population
[20,48,51,52]. Both studies reporting on co-receptor
usage in Malawian populations did not identify a single
X4-strain in both an adult [52] and paediatric [48] popu-
lation. Others have published higher prevalences of X4-
strains in HIV-1 subtype C-infected patients, however
these reports came from Zimbabwe and South Africa and
concerned adults in end-stage HIV infection (17–36%)
[20,51]. Furthermore, this prevalence is remarkable since
most children will have been vertically infected which is
commonly considered to occur by R5 variants [9]. Previ-
ous studies have suggested that the occurrence of X4
strains in subtype C infections was associated with the use
of anti-retroviral therapy (ART) [51]. No child was receiv-
ing ART at the time of this study.
The link between the occurrence of an X4 strain and dis-
ease progression is well studied in HIV-1 subtype B-
infected persons. Little data is available concerning this
association in HIV-1 subtype C-infected individuals. Our
results suggest X4 variants are not uncommon in a HIV-1
subtype C-infected population and their survival, espe-
cially in the presence of anaemia, may be limited. There-
fore more attention should be given to the clinical
importance of the occurrence of this variant in HIV-1 sub-
type C infected children and adults.
A limitation of our study is that we used indirect measures
to define co-receptor affinity rather than to assess actual
infectivity of cell-lined expressing CXCR4 or CCR5. Since
the C-PSSM method applied had a 94% specificity and
75% sensitivity [25], we might have underestimated X4
Distribution of potential N-linked glycosylation sites on V1-V2-V3 per study group Figure 5
Distribution of potential N-linked glycosylation sites on V1-V2-V3 per study group. Distribution of number of 
potential N-linked glycosylation sites on the V1-V2-V3 fragment in children with severe anaemia (cases, Hb<5.0 g/dL) as com-
pared to those without severe anaemia (controls). The distribution is expressed as a percentage of the total number of frag-
ments analysed per study group (Controls: n = 25, Cases n = 26). Error bars express 95%. p = 0.75.BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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tropism in our entire population. Since this underestima-
tion would have affected both our cases and controls it is
unlikely to have had a major impact effect on our find-
ings. We therefore did not pursue assessing our hypothesis
using the more costly and laborious exercise of infecting
cell lines expressing CXCR4 and CCR5. Although our data
cannot fully refute an association between X4 strains and
severe anaemia, X4 tropism is not a major cause of severe
anaemia.
The study had several strengths including the case-control
design and the long term follow-up period. This allowed
a cross-sectional analysis of X4 infected children with a
longitudinal assessment. We hypothesized that the occur-
rence of an X4 strain would predispose to severe anaemia.
The cross-sectional design used may have been underpow-
ered to detect a difference finding only four X4-infected
children. However none of these four children developed
a new episode of severe anaemia in the longitudinal
study. This may be considered additional evidence against
our hypothesis. Another strong point of the study was the
availability of bone marrow samples in a subgroup of
patients. The similarity of these isolates to those obtained
from the peripheral blood argues against compartmental-
isation in the bone marrow and strengthens our findings.
Conclusion
In summary, we assessed whether HIV-1 env characteris-
tics and CXCR4 co-receptor affinity were associated with
the occurrence of severe anaemia in Malawian children. In
this first study assessing clinical relevance we were unable
to find any differences either by phylogenetic analysis and
several tests used to assess co-receptor usage. We identi-
fied a relatively high prevalence of X4 strains in these HIV-
1 subtype C-infected children that were young, most likely
vertically infected and naïve to anti-retroviral therapy.
More attention should be given to the clinical importance
of the occurrence of this variant in HIV-1 subtype C
infected children and adults.
Boxplots of V1-V2 length per study group Figure 6
Boxplots of V1-V2 length per study group. Distribution of number of length of the V1-V2 fragment in children with 
severe anaemia (cases, Hb<5.0 g/dL) as compared to those without severe anaemia (controls). The length is expressed as in 
basepairs (bp). The analysis included 29 controls and 29 cases. Error bars express 95% confidence intervals, outliers are pre-
sented by dots. p = 0.55BMC Infectious Diseases 2008, 8:26 http://www.biomedcentral.com/1471-2334/8/26
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